Wealthcare Advisory Partners LLC Purchases Shares of 8,255 Guardant Health, Inc. (NASDAQ:GH)

Wealthcare Advisory Partners LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GHFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,255 shares of the company’s stock, valued at approximately $252,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Lord Abbett & CO. LLC bought a new stake in shares of Guardant Health in the 3rd quarter valued at $15,624,000. Cerity Partners LLC increased its stake in Guardant Health by 54.6% in the third quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock valued at $4,473,000 after purchasing an additional 68,883 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after purchasing an additional 29,686 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Guardant Health by 1,282.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after purchasing an additional 1,137,482 shares in the last quarter. Finally, First Light Asset Management LLC grew its stake in shares of Guardant Health by 119.7% in the 2nd quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock valued at $12,042,000 after buying an additional 227,202 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at $228,675.20. The trade was a 27.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,548 shares of company stock valued at $179,782. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

GH has been the subject of several recent research reports. Sanford C. Bernstein decreased their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Leerink Partners decreased their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Fifteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $40.60.

Check Out Our Latest Analysis on GH

Guardant Health Price Performance

GH opened at $45.13 on Wednesday. The firm has a market cap of $5.58 billion, a PE ratio of -10.64 and a beta of 1.28. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $45.68. The stock has a 50-day moving average price of $34.21 and a 200-day moving average price of $29.13.

Guardant Health (NASDAQ:GHGet Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.73) EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -3.44 EPS for the current year.

Guardant Health Company Profile

(Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Stories

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHFree Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.